Novavax, Inc. (NVAX) Hammered 9.7%: Factors To Watch On May, 09

Novavax, Inc. (NASDAQ:NVAX) is a big mover this session as the company shares are trading 9.7% or 0.039 points lower from last closing price of $0.4, reaching $0.3612 at last check. So what’s going on with NVAX shares anyway? The price has dropped in 4 of the last 5 days and is down -82.57% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -5,532,465 shares, and in total 3.65 million shares valued at $1.318 million were seen changing hands compared with 9.182 million shares valued at $3.673 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the NVAX stock is near its bottom.

Novavax, Inc. (NVAX) shares have notched a 3-month decline of about -82.57%, but has still tumbled -78.22% year to date. By comparison, the stock sank -75.26% over the past 12 months, while it slipped -29.77% over the 1 month. The company’s market cap is around $193.77M, with its short interest ratio standing at 5.42%.

In the current trading session for NVAX, the stock witnessed two major price actions, it rose to a high of $0.3822 and was down as much as $0.3612 at one point. The high recorded is very low when compared to their 52-week high which is $0.36. The 52-week high is now at -85.56 distance from current price. Their recent low of $2.58 represents a 3.5% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for NVAX is $1.46, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Novavax, Inc. earned $-0.5 per share in the trailing 12 months and has a P/E ratio of -0.72. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.82 and lower compared to the sector’s average of 59.56. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. NVAX also has P/S multiple of 5.09. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 44.54x.

The company recorded an interesting insider purchase transaction by the Director on Mar 27, 2019. A Securities and Exchanges Commission filings show that Rachel K King bought a total of 86,000 NVAX shares that day for a sum of around $45,580. The filings show that the insider stake has now grown to 42,000 shares, currently worth $15,170. Novavax, Inc. (NVAX) insiders have acquired 86,000 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded 86,000 shares in the business, which makes up 30.478% of 282,175 shares that were traded over a year. In the past 12 months, insiders have purchased 282,175 shares while the seller parted with shares.

NVAX‘s last price was down -75.32% as compared to the average trading price of 50 days recorded at $1.46 while enlarging the period to 200 trading days, the average closing price was $0.56. At present, there are 483.47 million in the total number of common shares owned by the public and among those 464.98 million shares have been available to trade. The percentage of shares being held by the company management was 0.95% while institutions stake was 34.6%. The company has generated positive returns on equity over the last 12 months (153.4%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the NVAX stock, there is another set of technicals that should be looked into and considered. Its -27.05% decline from moving average of $0.5 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.98 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Novavax, Inc. — 5 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 2 giving it a sell rating. Analysts arrived at a 12-month price target of $2.9375 on shares of Novavax, Inc. (NASDAQ:NVAX), which corresponds to 715.07% upside potential than its current market price of $0.3612 and implies potential despite the recent drop in the price. However, their current target price has fallen from $2.9538 a month ago and is down handily from the consensus target of $4.45 a quarter ago.

In the last five years, the EPS of the company has been roughly -10.3%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 10.4 over the last five years. The company recently recorded a drop of -41.3%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards NVAX stock. Great West Life Assurance Co. Can added position in the company after it grew 30.6% or 45,238 shares of its common stock. The hedge fund now owns 59,081 shares worth $21,340, SEC documents show. Raymond James Financial Services Advisors Inc. cut assets in the stock as 140585.2 shares have been sold, reducing its stake by -46% to 75,916 shares which are currently valued at $27,421. In addition, Regentatlantic Capital LLC recently reported that it now owns 60,000 shares making a total of $21,672 based on the recent price. This refelects a change of -50% in their ownership.